Shamburg News · 8-K filed Nov 12, 2026, 4:15 PM EST
BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
BLSM · BlossomHill Therapeutics, Inc.
- Earnings
- Financial statements
- Materiality: high
BlossomHill Therapeutics reported a third-quarter 2026 net loss of $24.0 million, or $(1.29) per basic and diluted share, compared with $16.0 million, or $(6.54) per share, a year earlier. R&D expenses were $21.9 million and G&A expenses were $3.6 million for the quarter. The company reported $224.9 million in cash and cash equivalents as of September 30, 2026, and said it expects that balance to fund operations into the second quarter of 2028.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-458447.
Written from the filing by Shamburg Markets. Figures are as reported by the company.